Company Overview: Islet Sciences

Industry News

30 Nov

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) and (IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its U.S. marketing partner, Par Pharmaceutical Inc. (“Par”), has launched...

Read more

18 Apr

Islet Sciences Appoints Dr. Gary Blackburn, Senior Pharma and Diagnostics Executive at Roche, Genmark, Motorola, and other Global Healthcare Enterprises, to the Board of Directors

NEW YORK, NY / ACCESSWIRE / April 18, 2016 / Islet Sciences, Inc. (OTC: ISLT) (“Islet Sciences”), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention and pre-treatment to prevent and slow the progression of metabolic disease, today announced that Dr. Gary Blackburn has been...

Read more

15 Mar

Islet Sciences Appoints Thomas J. Kindt, Ph.D., Former Division Head at NAID, NIH, to Islet Sciences Scientific Advisory Board

NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Islet Sciences, Inc. (OTC: ISLT) (“Islet Sciences”), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention, and pre-treatment to prevent and slow the progression of metabolic disease, today announced that it has appointed Thomas J....

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address